|
||||||
|
 | |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
|
Gene: ENSG00000171490 |
Summary for RSL1D1 |
 Gene summary |
| Gene information | Ensembl ID | ENSG00000171490 | Gene symbol | RSL1D1 |
| Gene name | ribosomal L1 domain containing 1 | |
| HGNC | 24534 | |
| Entrez ID | 26156 | |
| Gene type | protein_coding | |
| Synonyms | RSL1D1|PBK1|L12|DKFZP564M182|CSIG|UTP30 | |
| UniProtAcc | O76021 |
| Drugs associated with this gene(DrugBank). |
| Gene ID | Gene Symbol | Drug ID | Drug Name | Drug Type |
| Cancer therapeutic drugs associated with this gene(NCI). |
| Gene ID | Gene Name | Drug ID | Drug Name | Drug Type | Cancer |
Top |
Structure and expression level for RSL1D1 |
| AS events and RNA A-to-I editing events of the gene in TCGA based on Genvode V22 structure. ∗For more information on exon skipping events please check the ExonskipDB database. ∗For more information on exon skipping events please check the CAeditome database. |
 |
| Landscape of gene expressions across multiple cancer types. |
 |
| Differentially expressed gene analysis between tumor male and tumor female samples. |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| Differentially expressed gene analysis between tumor male and normal male samples. |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| Differentially expressed gene analysis between tumor female and normal female samples. |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
Top |
Sex-biased somatic mutation for RSL1D1 |
| ∗For more information on exon skipping events please check the ExonskipDB database. |
| Gene ID | Cancer Type | Hugo Symbol | Male | Female | pval | or | ci.up | ci.low | adjPval |
Top |
DNA methylation with beta values for RSL1D1 |
| Landscape of DNA methylation across multiple cancer types. |
 |
| Differentially expressed CpG sites between male tumor and female tumor patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| Differentially expressed CpG sites between male tumor and male normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| KIRC | cg05852052 | chr16:11852258 | CGI:chr16:11851208-11851660 | promoter | 2.85e-01 | 1.84e-01 | 2.92e+00 | 3.48e-03 | 4.67e-03 | 1.01e-01 |
| Differentially expressed CpG sites between female tumor and female normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
Top |
Exon skipping events with PSI in TCGA for RSL1D1 |
| ∗Please access ExonSkipDB for exon skipping annotation. |
| Landscape of exon skipping events across multiple cancer types. |
 |
| Differentially expressed exon skipping events between male tumor and female tumor patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| Differentially expressed exon skipping events between male tumor and male normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| Differentially expressed exon skipping events between female tumor and female normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
Top |
RNA A-to-I editing events in TCGA for RSL1D1 |
| ∗Please access CAeditome for RNA editing annotation. |
| Landscape of RNA editing events across multiple cancer types. |
 |
| Differentially expressed RNA editing events between male tumor and female tumor patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| KIRC | RSL1D1-001 | chr16_11835320_- | 2.25e-01 | 2.01e-01 | 2.49e+00 | 1.28e-02 | 4.28e-02 | 2.44e-02 |
| KIRC | RSL1D1-001 | chr16_11835346_- | 2.64e-01 | 2.36e-01 | 2.50e+00 | 1.22e-02 | 4.23e-02 | 2.77e-02 |
| KIRC | RSL1D1-001 | chr16_11835590_- | 1.41e-01 | 1.31e-01 | 2.01e+00 | 4.47e-02 | 4.96e-02 | 9.08e-03 |
| LUAD | RSL1D1-001 | chr16_11834963_- | 1.84e-01 | 2.22e-01 | -2.37e+00 | 1.77e-02 | 3.62e-02 | -3.82e-02 |
| LGG | RSL1D1-001 | chr16_11835094_- | 2.88e-01 | 2.68e-01 | 2.08e+00 | 3.74e-02 | 4.81e-02 | 2.00e-02 |
| THCA | RSL1D1-001 | chr16_11834963_- | 1.97e-01 | 1.51e-01 | 2.86e+00 | 4.25e-03 | 4.77e-02 | 4.54e-02 |
| THCA | RSL1D1-001 | chr16_11835350_- | 1.79e-01 | 1.53e-01 | 2.21e+00 | 2.71e-02 | 4.91e-02 | 2.60e-02 |
| THCA | RSL1D1-001 | chr16_11835626_- | 1.56e-01 | 1.37e-01 | 2.81e+00 | 4.99e-03 | 4.77e-02 | 1.93e-02 |
| HNSC | RSL1D1-001 | chr16_11835094_- | 3.72e-01 | 3.99e-01 | -2.03e+00 | 4.19e-02 | 4.72e-02 | -2.62e-02 |
| LUSC | RSL1D1-001 | chr16_11835320_- | 2.26e-01 | 1.96e-01 | 2.11e+00 | 3.50e-02 | 4.91e-02 | 3.00e-02 |
| LUSC | RSL1D1-001 | chr16_11835626_- | 1.39e-01 | 1.72e-01 | -3.22e+00 | 1.28e-03 | 4.91e-02 | -3.30e-02 |
| STAD | RSL1D1-001 | chr16_11834869_- | 2.47e-01 | 1.58e-01 | 1.98e+00 | 4.81e-02 | 4.96e-02 | 8.89e-02 |
| READ | RSL1D1-001 | chr16_11835320_- | 2.99e-01 | 2.19e-01 | 2.11e+00 | 3.48e-02 | 4.94e-02 | 7.98e-02 |
| READ | RSL1D1-001 | chr16_11835346_- | 2.31e-01 | 3.41e-01 | -2.34e+00 | 1.91e-02 | 4.85e-02 | -1.09e-01 |
| Differentially expressed RNA editing events between male tumor and male normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| KIRC | RSL1D1-001 | chr16_11834868_- | 2.23e-01 | 1.88e-01 | 2.34e+00 | 1.95e-02 | 2.79e-02 | 3.48e-02 |
| KIRC | RSL1D1-001 | chr16_11834879_- | 2.79e-01 | 2.33e-01 | 3.32e+00 | 8.89e-04 | 3.41e-03 | 4.61e-02 |
| KIRC | RSL1D1-001 | chr16_11835094_- | 4.20e-01 | 3.67e-01 | 2.91e+00 | 3.59e-03 | 9.10e-03 | 5.36e-02 |
| KIRC | RSL1D1-001 | chr16_11835346_- | 2.64e-01 | 2.17e-01 | 2.47e+00 | 1.37e-02 | 2.20e-02 | 4.64e-02 |
| HNSC | RSL1D1-001 | chr16_11834868_- | 2.15e-01 | 1.52e-01 | 2.18e+00 | 2.95e-02 | 3.30e-02 | 6.28e-02 |
| HNSC | RSL1D1-001 | chr16_11835346_- | 2.17e-01 | 1.44e-01 | 2.04e+00 | 4.11e-02 | 4.27e-02 | 7.26e-02 |
| LUSC | RSL1D1-001 | chr16_11834879_- | 2.42e-01 | 1.89e-01 | 2.40e+00 | 1.64e-02 | 2.61e-02 | 5.31e-02 |
| LUSC | RSL1D1-001 | chr16_11834989_- | 5.64e-01 | 4.77e-01 | 3.82e+00 | 1.35e-04 | 1.32e-03 | 8.76e-02 |
| LUSC | RSL1D1-001 | chr16_11835320_- | 2.26e-01 | 1.57e-01 | 2.07e+00 | 3.86e-02 | 4.30e-02 | 6.92e-02 |
| COAD | RSL1D1-001 | chr16_11835094_- | 3.32e-01 | 2.45e-01 | 2.51e+00 | 1.20e-02 | 1.94e-02 | 8.70e-02 |
| LIHC | RSL1D1-001 | chr16_11834956_- | 2.37e-01 | 1.59e-01 | 2.41e+00 | 1.61e-02 | 3.45e-02 | 7.87e-02 |
| LIHC | RSL1D1-001 | chr16_11834963_- | 2.43e-01 | 1.40e-01 | 2.97e+00 | 2.99e-03 | 2.14e-02 | 1.04e-01 |
| LIHC | RSL1D1-001 | chr16_11835094_- | 5.12e-01 | 4.32e-01 | 2.05e+00 | 4.00e-02 | 4.64e-02 | 8.04e-02 |
| ESCA | RSL1D1-001 | chr16_11834989_- | 6.23e-01 | 3.83e-01 | 3.75e+00 | 1.78e-04 | 5.37e-03 | 2.40e-01 |
| KICH | RSL1D1-001 | chr16_11835002_- | 1.66e-01 | 1.36e-01 | 2.05e+00 | 4.04e-02 | 4.41e-02 | 3.01e-02 |
| Differentially expressed RNA editing events between female tumor and female normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| BRCA | RSL1D1-001 | chr16_11834868_- | 2.31e-01 | 1.67e-01 | 5.97e+00 | 2.31e-09 | 1.34e-08 | 6.44e-02 |
| BRCA | RSL1D1-001 | chr16_11834879_- | 2.45e-01 | 1.97e-01 | 4.12e+00 | 3.81e-05 | 1.05e-04 | 4.75e-02 |
| BRCA | RSL1D1-001 | chr16_11834963_- | 2.03e-01 | 1.33e-01 | 2.36e+00 | 1.84e-02 | 2.29e-02 | 6.94e-02 |
| BRCA | RSL1D1-001 | chr16_11834989_- | 6.72e-01 | 5.60e-01 | 8.76e+00 | 1.90e-18 | 3.84e-17 | 1.11e-01 |
| BRCA | RSL1D1-001 | chr16_11835002_- | 1.83e-01 | 1.41e-01 | 4.42e+00 | 9.86e-06 | 3.07e-05 | 4.15e-02 |
| BRCA | RSL1D1-001 | chr16_11835094_- | 4.85e-01 | 3.22e-01 | 9.11e+00 | 8.47e-20 | 2.04e-18 | 1.63e-01 |
| BRCA | RSL1D1-001 | chr16_11835320_- | 2.66e-01 | 1.59e-01 | 6.52e+00 | 6.96e-11 | 5.15e-10 | 1.07e-01 |
| BRCA | RSL1D1-001 | chr16_11835346_- | 3.12e-01 | 1.76e-01 | 8.22e+00 | 1.96e-16 | 3.10e-15 | 1.36e-01 |
| THCA | RSL1D1-001 | chr16_11835320_- | 2.42e-01 | 1.80e-01 | 2.77e+00 | 5.58e-03 | 1.16e-02 | 6.21e-02 |
| BLCA | RSL1D1-001 | chr16_11835094_- | 3.89e-01 | 2.25e-01 | 2.74e+00 | 6.11e-03 | 3.32e-02 | 1.64e-01 |
| STAD | RSL1D1-001 | chr16_11834989_- | 6.04e-01 | 4.59e-01 | 2.14e+00 | 3.22e-02 | 4.29e-02 | 1.45e-01 |
| LIHC | RSL1D1-001 | chr16_11835590_- | 1.94e-01 | 1.38e-01 | 2.27e+00 | 2.33e-02 | 3.97e-02 | 5.54e-02 |
| Protein coding RNA editing(s). |
| Editing Position | Variant Type | Gene Symbol | Transcript ID | NTchange | AAchange |
Top |
Sex-biased TF-Gene network for RSL1D1 |
| TFs related to RSL1D1. ∗The female-biased TF-gene edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased TF-gene edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
 |
| Cancer Type | TF | Target Gene | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| BLCA | SP1 | RSL1D1 | 4.15e+00 | 9.85e-01 | 2.99e+00 | 2.82e-03 | Male-biased |
| BLCA | ZNF30 | RSL1D1 | 4.14e+00 | 9.82e-01 | 3.20e+00 | 5.82e-03 | Male-biased |
| BLCA | ZNF441 | RSL1D1 | 4.20e+00 | 9.82e-01 | 3.31e+00 | 7.03e-03 | Male-biased |
| BLCA | ZNF571 | RSL1D1 | 4.08e+00 | 9.81e-01 | 3.10e+00 | 5.05e-03 | Male-biased |
| BRCA | ZNF235 | RSL1D1 | 4.71e+00 | 9.82e-01 | 3.54e+00 | 1.21e-02 | Male-biased |
| ESCA | NRF1 | RSL1D1 | 4.48e+00 | 9.83e-01 | 3.79e+00 | 1.16e-02 | Male-biased |
| LAML | ALX1 | RSL1D1 | 4.85e+00 | 9.84e-01 | 3.96e+00 | 1.09e-02 | Male-biased |
| LAML | ALX4 | RSL1D1 | 5.16e+00 | 9.81e-01 | 4.37e+00 | 1.59e-02 | Male-biased |
| LAML | FOXA2 | RSL1D1 | 4.52e+00 | 9.85e-01 | 3.46e+00 | 5.93e-03 | Male-biased |
| LAML | FOXB1 | RSL1D1 | 4.70e+00 | 9.89e-01 | 3.58e+00 | 4.69e-03 | Male-biased |
| LAML | HNF1A | RSL1D1 | 4.65e+00 | 9.80e-01 | 3.79e+00 | 1.25e-02 | Male-biased |
| LAML | NEUROD1 | RSL1D1 | 4.88e+00 | 9.81e-01 | 4.05e+00 | 1.37e-02 | Male-biased |
| LAML | NKX3-1 | RSL1D1 | 5.02e+00 | 9.87e-01 | 4.09e+00 | 9.33e-03 | Male-biased |
| LAML | PHOX2B | RSL1D1 | 4.99e+00 | 9.82e-01 | 4.15e+00 | 1.34e-02 | Male-biased |
| LAML | TBP | RSL1D1 | 4.67e+00 | 9.80e-01 | 3.82e+00 | 1.29e-02 | Male-biased |
| LAML | UNCX | RSL1D1 | 5.03e+00 | 9.81e-01 | 4.23e+00 | 1.54e-02 | Male-biased |
| LAML | ZNF25 | RSL1D1 | 4.73e+00 | 9.89e-01 | 3.61e+00 | 4.64e-03 | Male-biased |
| LAML | ZNF584 | RSL1D1 | 4.46e+00 | 9.81e-01 | 3.53e+00 | 9.11e-03 | Male-biased |
| LAML | ZNF879 | RSL1D1 | 4.80e+00 | 9.85e-01 | 3.87e+00 | 9.51e-03 | Male-biased |
| RSL1D1 related gene. ∗Only the gene encode TF might with this result. ∗For more information please check Sex-biased TF-Coding gene network. |
Top |
Sex-biased RBP-ES network for RSL1D1 |
| RBPs related to ES in RSL1D1. ∗The female-biased RBP-ES edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased RBP-ES edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
 |
| Cancer Type | RBP | Target ES | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| UVM | RBM5 | exon_skip_142002 | 9.39e+00 | 9.84e-01 | 9.11e+00 | 1.31e-02 | Male-biased |
| PCPG | RBM5 | exon_skip_142002 | 9.34e+00 | 9.83e-01 | 9.04e+00 | 1.34e-02 | Male-biased |
| KIRC | SRSF2 | exon_skip_141991 | 9.00e+00 | 9.81e-01 | 8.72e+00 | 1.45e-02 | Male-biased |
| RSL1D1 related ES. ∗Only the gene encode RBP might with this result. ∗For more information please check Sex-biased RBP-ES network in cancer. |
Top |
Sex-biased CeRNA regulation of gene |
| Sex-biased CeRNA regulation of gene. |
| Gene ID | ceRNA(lncRNA-miRNA-mRNA) | Group | Cancer Type |
Top |
Sex-biased eQTL regulation of gene |
| Sex-biased eQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| eQTL | Description |
| Male-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| rs2545886 | chr16:21017875:A:G | - | 0.234972351407894 | 0.00644704964748077 | GBM | Female-baised eQTL |
| rs330150 | chr16:21039887:G:C | - | 0.224830216076478 | 0.0237508507867728 | GBM | Female-baised eQTL |
| rs276639 | chr16:13085159:G:A | - | 0.193182143241198 | 0.0319944539600839 | GBM | Female-baised eQTL |
| rs276638 | chr16:13085864:C:G | - | 0.193182143241198 | 0.0319944539600839 | GBM | Female-baised eQTL |
| rs276608 | chr16:13079905:T:G | - | 0.188166865156545 | 0.0470813313238926 | GBM | Female-baised eQTL |
| rs276603 | chr16:13081132:T:C | - | 0.188166865156545 | 0.0470813313238926 | GBM | Female-baised eQTL |
| rs276642 | chr16:13083650:A:G | - | 0.204390780226412 | 0.0497495002751568 | GBM | Female-baised eQTL |
| rs3104704 | chr16:9974095:A:G | - | -0.183215732032012 | 0.0151482172103147 | KIRP | Female-baised eQTL |
| rs3104707 | chr16:9977301:A:G | - | -0.16418481530427 | 0.0195184443550363 | KIRP | Female-baised eQTL |
| rs1650409 | chr16:10269565:C:T | - | -0.219419530418705 | 0.0229431757032231 | KIRP | Female-baised eQTL |
| rs3105687 | chr16:9970112:A:G | - | -0.174415785829817 | 0.0331233233639778 | KIRP | Female-baised eQTL |
| rs2650422 | chr16:9994603:G:C | - | -0.169712403706637 | 0.0419010446150605 | KIRP | Female-baised eQTL |
| rs73511456 | chr16:11311571:C:T | - | 0.146877824959637 | 0.0434076309468483 | KIRP | Female-baised eQTL |
| rs929879 | chr16:11312284:G:A | - | 0.146877824959637 | 0.0434076309468483 | KIRP | Female-baised eQTL |
| rs3790125 | chr16:10530721:A:G | - | 0.186746011072111 | 0.0231206399134238 | LUSC | Female-baised eQTL |
| rs3790124 | chr16:10530722:G:A | - | 0.186746011072111 | 0.0231206399134238 | LUSC | Female-baised eQTL |
| rs10459782 | chr16:10531318:G:A | - | 0.186746011072111 | 0.0231206399134238 | LUSC | Female-baised eQTL |
| rs2047923 | chr16:10532332:G:A | - | 0.194895480399532 | 0.0231751386411414 | LUSC | Female-baised eQTL |
| rs12051183 | chr16:10533648:G:C | - | 0.191376749650458 | 0.0234263455068227 | LUSC | Female-baised eQTL |
| rs3790127 | chr16:10530585:T:C | - | 0.183879028553623 | 0.0292329179959032 | LUSC | Female-baised eQTL |
| rs9972772 | chr16:10527165:C:G | - | 0.181669263967793 | 0.0408664413611652 | LUSC | Female-baised eQTL |
| rs9972773 | chr16:10527233:C:T | - | 0.181669263967793 | 0.0408664413611652 | LUSC | Female-baised eQTL |
| rs3892151 | chr16:10527407:T:C | - | 0.181669263967793 | 0.0408664413611652 | LUSC | Female-baised eQTL |
| rs4786076 | chr16:6026016:C:T | - | 0.0855216181501801 | 0.0363059083139328 | KIRC | Female-baised eQTL |
| rs4781282 | chr16:12593727:G:A | - | 0.0558587384029434 | 0.00368338333960114 | LUAD | Female-baised eQTL |
| rs112827123 | chr16:12595135:T:C | - | 0.0530021654656441 | 0.00955917947970808 | LUAD | Female-baised eQTL |
| rs80226234 | chr16:12595096:A:C | - | 0.0529626191009962 | 0.00966391113487347 | LUAD | Female-baised eQTL |
| rs75253185 | chr16:12596272:C:G | - | 0.0543373595165658 | 0.0197889092833011 | LUAD | Female-baised eQTL |
| rs6498332 | chr16:12600423:G:A | - | 0.0525514880181043 | 0.0209754835507678 | LUAD | Female-baised eQTL |
| rs7192728 | chr16:12601092:T:C | - | 0.0525514880181043 | 0.0209754835507678 | LUAD | Female-baised eQTL |
| rs6498331 | chr16:12599325:A:T | - | 0.0525575577160107 | 0.0210397192480552 | LUAD | Female-baised eQTL |
| rs9927427 | chr16:12597926:T:A | - | 0.0525157891126747 | 0.021145206135593 | LUAD | Female-baised eQTL |
| rs4780461 | chr16:12599011:A:G | - | 0.0525157891126747 | 0.021145206135593 | LUAD | Female-baised eQTL |
| rs6498329 | chr16:12599212:T:C | - | 0.0525157891126747 | 0.021145206135593 | LUAD | Female-baised eQTL |
| rs138281351 | chr16:12595995:G:A | - | 0.051028338927575 | 0.0277858105089002 | LUAD | Female-baised eQTL |
| rs150976917 | chr16:12596456:T:A | - | 0.051028338927575 | 0.0277858105089002 | LUAD | Female-baised eQTL |
| rs8063491 | chr16:12597281:G:C | - | 0.0505767807233161 | 0.0290295247553117 | LUAD | Female-baised eQTL |
| rs75525228 | chr16:12595114:G:A | - | 0.0487979150381601 | 0.0290333101148666 | LUAD | Female-baised eQTL |
| rs7184622 | chr16:5841783:C:G | - | 0.0480524779846531 | 0.0351734497224439 | LUAD | Female-baised eQTL |
| rs4781292 | chr16:12597796:C:T | - | 0.0500195372299225 | 0.0379429629505528 | LUAD | Female-baised eQTL |
| rs4781291 | chr16:12597675:G:A | - | 0.0487258706396506 | 0.0404147797183535 | LUAD | Female-baised eQTL |
| rs4781284 | chr16:12593865:C:T | - | 0.0492981209914428 | 0.0418286782133096 | LUAD | Female-baised eQTL |
| rs9652603 | chr16:11450151:A:G | - | -0.0645853141858009 | 0.0425322546266649 | LUAD | Female-baised eQTL |
| rs7203183 | chr16:12593091:C:A | - | 0.0487860256471656 | 0.0451224742669909 | LUAD | Female-baised eQTL |
| rs10454063 | chr16:12594229:A:C | - | 0.0487860256471656 | 0.0451224742669909 | LUAD | Female-baised eQTL |
| rs77326840 | chr16:12595795:T:C | - | 0.0487860256471656 | 0.0451224742669909 | LUAD | Female-baised eQTL |
| rs9934480 | chr16:11448645:C:T | - | -0.0632218137150572 | 0.049442458393162 | LUAD | Female-baised eQTL |
| rs4303499 | chr16:11448656:A:G | - | -0.0632218137150572 | 0.049442458393162 | LUAD | Female-baised eQTL |
| Female-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| rs28553505 | chr16:4108538:C:G | - | 0.0964552224975964 | 0.0334545755151181 | HNSC | Male-baised eQTL |
| rs4787162 | chr16:8240103:G:A | - | 0.0407969692059918 | 0.0219447079408214 | LUSC | Male-baised eQTL |
| rs11649529 | chr16:19199952:C:T | - | 0.0581849931968304 | 0.0270179232409721 | BLCA | Male-baised eQTL |
| rs8046046 | chr16:8801499:A:T | - | -0.0804345502828617 | 0.0495303031043833 | BLCA | Male-baised eQTL |
| rs7192073 | chr16:8807875:A:C | - | -0.0804345502828617 | 0.0495303031043833 | BLCA | Male-baised eQTL |
| rs62017996 | chr16:8220044:A:G | - | 0.0599569960277859 | 0.0156249373411356 | LUAD | Male-baised eQTL |
| rs12149640 | chr16:8211315:G:A | - | 0.0557031704642084 | 0.0318400617669208 | LUAD | Male-baised eQTL |
| rs12928189 | chr16:7546177:A:G | - | -0.0688232510305694 | 0.00403929410542029 | COAD | Male-baised eQTL |
| rs1395585 | chr16:7544956:G:A | - | -0.0705747415502745 | 0.00977374041073958 | COAD | Male-baised eQTL |
| rs1507025 | chr16:7539229:A:G | - | 0.0675404686131902 | 0.022547128440183 | COAD | Male-baised eQTL |
| rs8060394 | chr16:7539187:T:C | - | -0.0622973892436241 | 0.0281429573627819 | COAD | Male-baised eQTL |
| rs755385 | chr16:19340971:T:C | - | -0.0737140830524683 | 0.03109202180383 | COAD | Male-baised eQTL |
| rs12933105 | chr16:7525286:T:C | - | -0.0519742590085547 | 0.0384379687992088 | COAD | Male-baised eQTL |
| rs2907344 | chr16:7760346:G:A | - | 0.0579003409527052 | 0.0391618518094925 | COAD | Male-baised eQTL |
| rs1981763 | chr16:11587866:T:C | - | -0.0662630807142392 | 0.0483527536111403 | COAD | Male-baised eQTL |
| Opposite sex-biased eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Sex-biased Gene in Cancer | Cancer Type |
Top |
Sex-biased eQTM regulation of gene |
| Sex-biased eQTM regulation of gene (The figures only show the pairs with FDR<1e-5. For more information please check the below table). |
| eQTM | Description |
 | Gene ID: ENSG00000171490 |
| CpG Site: cg02740093 | |
| Position to Gene: gene,exon,UTR | |
| Male Effect: -0.422501105383884 | |
| Female Effect: - |
| Male-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| cg02740093 | chr16:11836532 | gene,exon,UTR | -0.422501105383884 | 7.95466739699837e-14 | -0.5190714333577242 | 1.0287740725985842e-16 | LUAD |
| Female-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| Opposite sex-biased eQTM regulation. |
| CpG Site | CpG Postion | CpG Island | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Male Cor | Male P-value | Female Cor | Female P-value | Sex-biased Coding Gene | Cancer Type |
Top |
Sex-biased sQTL regulation of gene |
| Sex-biased sQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTL | Description |
| Male-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| Female-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| Opposite sex-biased sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Male Effect | Male FDR | Female Effect | Female FDR | Cancer Type |
Top |
Sex-biased sQTM regulation of gene |
| Sex-biased sQTM regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTM | Description |
| Male-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
| Female-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
| Opposite sex-biased sQTM regulation. |
| EX ID | EX Info | Skipped Exon | CPG Site | CPG Position | CPG Island | Position to EX Events | Male Effect | Male FDR | Female Effect | Female FDR | Male Correlation | Male P-value | Female Correlation | Female P-value | ORF_anno | Cancer Type |
Top |
Related disease information of RSL1D1 |
| Diseases associated with this gene (DisGeNET). |
| Gene ID | Gene Symbol | Disease ID | Disease Name | Number of PMID | Source |
